Cyril Amarchand Mangaldas and Clifford Chance advised book runners Nomura Financial Advisory & Securities (India), Axis Capital, JP Morgan India and Edelweiss Financial Services on the Rs 1,350 crore initial public offer (IPO) of Indian pharma global giant Alkem Laboratories. Alkem was advised by Khaitan & Co.
CAM Mumbai capital markets partner Gaurav Gupte and Clifford Chance Singapore partner Rahul Guptan acted for the four global coordinators and lead managers.
Khaitan Mumbai partner Abhimany Bhattacharya, executive director Sudhir Bassi, principal associate Soumya Mohapatra and associates Aanchal Arora, Aayush Mohata, Abir Sarkar and Srikant Mantravedi acted for Alkem.
The IPO of 12,853,442 Rs 2 equity shares for cash at a price of INR 1,050 per Equity Share, through an offer for sale by the selling shareholders, aggregating to Rs 13,46.62 crore, according to CAM’s press release.
The generic drugs maker had filed its prospectus for the IPO with SEBI in August, reported Business Standard.
The original version of this story overstated the size of the IPO. We regret the error.
threads most popular
thread most upvoted
comment newest
first oldest
first
threads most popular
thread most upvoted
comment newest
first oldest
first